

سامية محمد مصطفى



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى




شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل



**THE DIAGNOSTIC AND PROGNOSTIC VALUES OF THE
QUANTITATIVE ESTIMATION OF ENDOMETRIOSIS PROTEIN 1
GENE EXPRESSION IN TISSUE AND LYMPHOCYTE
SUBPOPULATION AND CA-125 IN SERUM IN WOMEN WITH
PELVIC ENDOMETRIOSIS RECEIVING GnRH AGONISTS
(GOSERELIN ACETATE): A COMPARATIVE PROSPECTIVE STUDY.**

A thesis submitted for partial fulfillment of M.D. degree in
Obstetrics and gynecology

By

MOHAMMED MAHMOUD AL SHERBEENY

M.B.B.Ch. M.Sc., (OB/GYN)

Assistant lecturer of OB/GYN

UNDER SUPERVISION OF

PROFESSOR HAMDI MOHAMED EL KABARITY

Chairman of the department of Obstetrics and Gynecology
Faculty of medicine - Ain Shams University

PROFESSOR MOHAMED ALY IBRAHIM

Professor of Obstetrics and Gynecology
Faculty of medicine - Ain Shams University

PROFESSOR ADEL MOHAMED EL MESSRY

Head of medical research center
Faculty of medicine - Ain Shams University


DR. NAHLA MOHAMED ZAKARIA

Assistant Professor of Clinical pathology
Faculty of medicine - Ain Shams University

2001

B

13194



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"أَنَا فَتَحْنَا لَكَ فَتْحًا مُبِينًا"

صدق الله العظيم
سورة الأية

ACKNOWLEDGEMENT

I would like to express my deepest gratitude and thanks for Professor Hamdi Mohamed El Kabarity, professor and chairman of ^{the} department of Obstetrics and Gynecology, Ain Shams University, who provided me with unlimited support, and continuous encouragement.

Sincere thanks are due to Professor Mohamed Aly Ibrahim, professor of Obstetrics & Gynecology, Ain Shams University, for his active support and faithful guidance.

No words can express my thanks to ^P professor Adel Mohamed El Messiry, ^H head of medical research center, Ain Shams University, for his precious help and fruitful guidance.

I am truly appreciative to Dr. Nahla Mohamed Zakaria, Assistant professor of ^P clinical pathology, Ain Shams University, for her active and valuable participation in this work.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

LIST OF CONTENTS

List of tables	iii
List of figures	v
List of abbreviations	xi
Introduction	1
Aim of the work	7
Review of literature	9
Chapter 1: What is endometriosis?	9
Chapter 2: Do all women have endometriosis?	25
Chapter 3: Classification of endometriosis	37
Chapter 4: The role of CA-125 in endometriosis	65
Chapter 5: Immunology of endometriosis	81
Chapter 6: Endometriosis protein 1	95
Chapter 7: GnRH in the treatment of endometriosis	101
Subjects and methods	123
Results	139

List of contents

Discussion	185
Limitations	195
Summary & Conclusions	197
Recommendations	201
References	203
Arabic summary	

LIST OF TABLES

Table 1-3: Classification of endometriosis proposed by the Endometriosis Study Group.	54
Table 2-3: Comparison of FOATI system with the revised American Fertility Society (AFS) classification, in a retrospective study of 459 patients.	64
Table 1-4: Results of laparoscopic diagnosis and clinical data.	71
Table 1-5: lymphocyte subsets in peripheral blood from normal individuals and patients with endometriosis before treatment.	83
Table 1-7: GnRH Agonists Studied for Gynecologic Conditions.	109
Table 2-7: The mean (\pm standard deviation) pharmacokinetic parameter estimates of ZOLADEX® after administration of 3.6 mg depot for 2 months in males and females.	114
Table 3-7: The adverse effects of ZOLADEX® compared to Danazol®.	119

1000
1000
1000

1000

1000
1000
1000

1000
1000

1000
1000
1000

1000
1000

1000
1000
1000

1000
1000

1000
1000

1000
1000

1000
1000